| Name | Halcinonide |
| Description | Halcinonide (Halciderm), a high-efficiency corticosteroid, is served as an anti-inflammatory agent used in topical preparations. |
| In vitro | After administering 0.1% Halcinonide cream for three days, the total number of peritoneal white blood cells in rats decreased from 270 million to 120.73 million. The same dosage of the drug, when applied to the surface of injured rat cecum for 3 and 7 days, significantly reduced the average adhesion scores, with the adhesion rates in the experimental and control groups being 43.3% and 100%, respectively. |
| In vivo | Halcinonide interacts with hormone receptors in the cytoplasm, eliciting anti-inflammatory effects. It is employed in the treatment of certain skin disorders. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (98.91 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 4 mg/mL (8.79 mM), Heating is recommended.
|
| Keywords | Inhibitor | SQ 18566 | inhibit | Smo | Halcinonide | SQ18566 | Smoothened |
| Inhibitors Related | Nimodipine | Hydrocortisone | Mifepristone | Prednisolone acetate | Cortisone | Dexamethasone acetate | Prednisolone | Dexamethasone | Dexamethasone Phosphate disodium | Prednisone acetate | Desonide | Corticosterone |
| Related Compound Libraries | Nuclear Receptor Compound Library | Reprogramming Compound Library | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
